Skip to main content
Default Image

The Case for a Public Option for the Drug Industry

Under siege from thousands of lawsuits from federal, state, and local governments for its role in the deadly opioid addiction crisis, drug manufacturer Purdue Pharma reached a tentative settlement with some of the plaintiffs last week. In the deal, Purdue would transform itself through the bankruptcy process from a typical, profit-chasing drugmaker into a “public beneficiary company.” The proposition raises an important question: If plaintiffs are open to the idea of turning Purdue into a public trust run by appointees of a federal bankruptcy judge—one that would distribute its profits to state and local governments—why not take one more step? Why not create the beginnings of a network of public pharmaceutical companies like those that already exists in such countries as Sweden, Brazil, and Thailand?

Publication date: 2019-09-15
Parent publication: New Republic
Publication URL: https://newrepublic.com/article/155071/case-public-option-drug-industry-purdue-pharma-settlement-bankruptcy

More related work

Medicine Cost

Americans deserve publicly owned generic drugs

Bold policies could have saved America’s largest generic drug plant, but it’s never too late to start putting communities first.

read more
Illustration courtesy of United Nations

All health is public health: Busting the myths of choice and commodity

For decades, we have been sold a myth of private health. It is a myth that our health is largely a product of individual choices and personal responsibilities. It is a myth that our healthcare is a service that private corporations can provide, and for which we must pay to survive. But the COVID-19

read more
Neil McInroy (Source: Coop News)

Neil McInroy joins TDC to advise stepped-up community wealth building program

The former CEO of a leading UK economic think tank will be central in helping build capacity to offer powerful new technical assistance to cities and local authorities pursuing community wealth building strategies.

read more